Tilray Brands delivered a quarter of record revenue and expanding margins that still missed on both lines. The company reported a fiscal first-quarter loss of $0.32 per share, against a consensus of -$0.19, a 68.4% shortfall. Revenue of $257.15 million rose 22.7% year over year but came in 2.9% below the $264.9 million consensus. The miss is largely a GAAP story: adjusted EPS was a much narrower -$0.02. Even so, that compares with an adjusted profit of $0.03 a year ago, so the deterioration is not purely an accounting artifact. The central tension is that BrewDog is reshaping Tilray's revenue mix and gross margin, while the cannabis franchise that defines the stock is shrinking and adjusted EBITDA moved backward.
The quality of the quarter deserves scrutiny. Gross profit rose 35% to $77.5 million, and consolidated gross margin expanded about 300 basis points to 30%. Operating expenses, however, rose 83%. G&A was up 40%, marketing and promotion up 55%, and transaction and restructuring costs together exceeded $7 million. The year-ago period also benefited from a $15 million contingent-consideration gain that did not recur. Adjusted EBITDA slipped to $9.2 million from $10.2 million, including about $1.7 million of fuel surcharges. Free cash flow was -$27.4 million versus -$10.6 million, pressured by a $27.8 million inventory build. Cash, restricted cash and marketable securities fell to $221.4 million from $264.8 million a year ago. Tilray also raised $22.3 million through share issuance, and shares outstanding climbed to 144.9 million from 131.7 million at the end of May.
The segment detail explains the headline growth. Beverage revenue jumped 82% to $101.5 million, and beverage gross margin reached 41%, up from 32% in the third quarter of fiscal 2026, which management had called the bottom. BrewDog contributed $55.9 million, turned profitable and required no cash injection. That is a meaningful reversal from the roughly $50 million of working-capital support disclosed last quarter. Excluding BrewDog, though, legacy U.S. beverage revenue declined. Cannabis was the weak spot. Segment revenue fell to $56.1 million from $64.5 million as Canadian adult-use gross sales dropped to $53.6 million from $64.1 million. Management attributed the decline to strain rotations, supply constraints and roughly one metric ton redirected abroad. That contrasts with the mid-single-digit growth narratives of prior calls. International cannabis grew 21% to $16.2 million, down sharply from 73% growth two quarters ago, and absorbed $8.8 million of price compression in a single quarter. Cannabis gross margin did improve to 39%, helped by Portugal cultivation costs falling about 40% and sharply higher EU-GMP volumes.
The forward story rests on catalysts that have not yet reached the income statement:
- The Carlsberg U.S. production and distribution partnership starts January 1, 2027, and management framed it as an immediate scale contributor.
- Management plans international BrewDog expansion through partnerships and franchises.
- U.S. craft beer is showing share gains.
- Canadian THC beverage channels could expand.
The risks are concrete. They include German reimbursement changes on oils, possible consolidation among large international cannabis competitors, the uncertain December U.S. hemp-THC beverage deadline, and $52 million of convertible notes maturing in June 2027 alongside continued ATM dilution. Tilray reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million rather than raising it. After a $9.2 million first quarter, that target requires a pronounced back-half ramp, which management attributes to normal seasonality.
The call's tone was notably more defensive than earlier ones. Prior quarters led with rescheduling optimism and the BrewDog launch. This time management emphasized that Tilray no longer depends on any single regulatory catalyst and voiced frustration with the stock's valuation. Investors have not been persuaded. Earnings Whispers investor sentiment weakened from 0.074 to 0.008, sliding from mildly positive to essentially neutral. Shares hit a 52-week low of $3.38 on report day and now trade at $3.54. That is 12.2% below the open following the July report and 40.8% under the 200-day moving average of $5.98. AVWAP readings remain negative, while price and momentum trends are only neutral.
The bottom line is that Tilray's diversification thesis gained real evidence this quarter. BrewDog is profitable, beverage margins have recovered and the balance sheet still carries net cash. But those gains were offset by a contracting Canadian cannabis business, decelerating international growth, heavy price compression, lower adjusted EBITDA, rising cash burn and ongoing dilution. With guidance merely reaffirmed and dependent on a back-half surge, the burden of proof remains squarely on execution in the coming quarters. The market's treatment of the stock suggests few investors are willing to underwrite that ramp in advance.